The European Investment Bank (EIB) is lending €20 million to PRECISIS GmbH, a Heidelberg-based medical technology company, to advance development and expand its minimally invasive epilepsy treatment across Europe, the EIB announced. The venture debt loan will support clinical development, prepare for market expansion, scale up production, and enable greater market access. The financing is backed under the European Commission’s InvestEU initiative.
PRECISIS developed EASEE®, a low-invasive implant placed under the scalp that delivers targeted electrical pulses to epileptogenic brain regions. Unlike traditional deep brain stimulation or vagus nerve stimulation, EASEE® stimulates affected areas from above the skull—customizable to each patient and with much lower risk. Recent clinical data show 65% of patients reduced their seizures by at least half, median seizure frequency dropped by 68%, and 81% continued therapy after two years.
EIB Vice President Nicola Beer says the therapy is transforming the lives of epilepsy patients and their families.
“With €20 million of EIB venture debt financing, we are pleased to back PRECISIS and this pioneering work developed in Heidelberg and across Europe,” she said.
Karl Stoklosa, CEO of PRECISIS, calls the financing “a strong endorsement of our platform and vision” and says the company is now actively working with investors to complete its Series B round and speed up expansion to other European countries and then the U.S. market.
EASEE® has been CE-certified since 2022 and is now used in six European countries, including Germany, Austria, Switzerland, the UK, Portugal, and Italy, with Spain coming soon. Over 150 patients have been implanted so far. The market for neurostimulation systems is one of the fastest-growing segments in medical technology. Globally, around 15 million people have focal epilepsy, with roughly one-third not responding well to medication.
